SynthesisOncotarget2017
Interleukin-6-174G>C gene promoter polymorphism and prognosis in patients with cancer.
Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tumor necrosis factor-alpha-308 gene promoter polymorphism associates with survival of cancer patients: A meta-analysis.Medicine · 2018Pooled it
- Impact of IL-6 and IL-1β Gene Variants on Non-small-cell Lung Cancer Risk in Egyptian Patients.Biochemical genetics · 2024Article
- Association of interleukin6 rs1800796 gene polymorphism and serum level with bladder cancer in Egyptian population.Molecular biology reports · 2024Article
- Evaluation the -174G>C Genetic Polymorphism of Interleukin-6 in Iranian Patients with Chronic Lymphocytic Leukemia.Iranian journal of pathology · 2023Article
- Association of IL-6 -174G>C and -572G>C Polymorphisms with Susceptibility to Cervical Cancer and Ovarian Cancer.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Effects of the IL6 -174G>C promoter polymorphism and IL-6 serum levels on the progression of cutaneous malignant melanoma.Oncology letters · 2020Article
- STAT3 polymorphisms and IL-6 polymorphism are associated with the risk of basal cell carcinoma in patients from northern Poland.Archives of dermatological research · 2019Article
- Article
- Association between the rs1800795G>C polymorphism in the promoter of interleukin-6 gene and bladder cancer.International journal of clinical and experimental pathology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-6 (IL-6) is known to be involved in the pathogenesis of cancer progression. IL-6-174G>C polymorphism has shown several results in association studies. In this study, we evaluated the association the IL-6-174G>C polymorphism and overall survival (OS) of cancer using 17 eligible studies with 4,304 patients. Our meta-analysis indicated that IL-6-174G>C polymorphism is not associated with OS when assessed using 3 genotype comparison including GG/(GC+CC), CC/(GC+GG) and CC/GG. Interestingly, compared to GG carrier, patients with IL-6-174GC genotype showed a decreased hazard of poor OS (hazard ratio = 0.81, 95% confidence interval: 0.68-0.96, P = 0.018; I2 = 34.5%, Phet = 0.107). However, for GG/(GC+CC) genotype comparison, this SNP is affect patients' OS obviously in bladder cancer, ovarian and peritoneal cancer, neuroblastoma, gastric cancer and osteosarcoma, though pooled results showing negative association because adverse and protective effect on different type of cancer balance each other. These results suggest IL-6-174G>C polymorphism might play a role in modulating OS in different type of cancer and might contribute to individual treatment in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.